Headache News and Research

Latest Headache News and Research

TOBI Podhaler receives FDA approval for cystic fibrosis patients with Pseudomonas aeruginosa

The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes lung infections.

24 Mar 2013

Roundup: Medicaid causes budget headache in Wash. state; Minn. plan to cut health services a surprise; Midwife access issues in N.C.

A selection of health policy stories from Washington state, Minnesota, North Carolina, Tennessee, Georgia, Arizona, California and Colorado.

22 Mar 2013

Fibromyalgia: an interview with Dr Frederick Wolfe, University of Kansas School of Medicine

Fibromyalgia is a common disorder that is diagnosed in people who have pain in many areas of their body together with important symptoms such as...

22 Mar 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors).

21 Mar 2013

Dotarem gets FDA approval for use in patients undergoing CNS MRI

The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging of the brain, spine and associated tissues of patients ages 2 years and older.

21 Mar 2013

Migraine severity may be predicted by blood levels of fat cell hormone

In a small, preliminary study of regular migraine sufferers, scientists have found that measuring a fat-derived protein called adiponectin (ADP) before and after migraine treatment can accurately reveal which headache victims felt pain relief.

18 Mar 2013

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

The following research from Columbia University Medical Center and NewYork-Presbyterian Hospital is being presented at the 65th annual meeting of the American Academy of Neurology, March 16-23, 2013, in San Diego.

18 Mar 2013

New procedure to treat pseudotumor cerebri

A team of interventional neuroradiologists and neurosurgeons at Johns Hopkins reports wide success with a new procedure to treat pseudotumor cerebri, a rare but potentially blinding condition marked by excessive pressure inside the skull, caused by a dangerous narrowing of a vein located at the base of the brain.

13 Mar 2013

Study shows brain areas undergo measureable volume loss after concussion

A single concussion may cause lasting structural damage to the brain, according to a new study published online in the journal Radiology.

12 Mar 2013

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Influenza or flu for short is caused by a family of viruses, which can be called influenza A or influenza B. Influenza A viruses are found in humans, animals – like swine and horses- and mostly aquatic birds. Influenza B is only found in humans.

11 Mar 2013

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags.

6 Mar 2013

FDA accepts AMAG’s Feraheme sNDA for review

AMAG Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for Feraheme (ferumoxytol) Injection for Intravenous (IV) use, which was submitted to the FDA in December 2012.

6 Mar 2013

Mirabegron reduces frequency of incontinence episodes in phase III trial

In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.

5 Mar 2013

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).

5 Mar 2013

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197 Protein)in adults infected with human immunodeficiency virus (HIV).

5 Mar 2013

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

4 Mar 2013

Orofacial treatment beneficial for headache plus temporomandibular disorder

Patients with features of cervicogenic headache who also show signs of temporomandibular disorder may benefit from receiving orofacial treatment in addition to usual cervical manual therapy care, say researchers in Manual Therapy.

28 Feb 2013

AHRF to present free symposium on dizziness and balance disorders

The American Hearing Research Foundation will present a free, day-long educational symposium on dizziness and balance disorders on Saturday, April 6 at the Hilton Suites Chicago/Oakbrook in Oakbrook, Illinois.

27 Feb 2013

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.

From Baxter International Inc. 26 Feb 2013

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

AstraZeneca today announced high-level results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related pain and opioid-induced constipation (OIC). UC was defined as the investigator's choice of an existing laxative treatment regimen for OIC.

26 Feb 2013

Headache News and Research

Latest Headache News and Research

TOBI Podhaler receives FDA approval for cystic fibrosis patients with Pseudomonas aeruginosa

Roundup: Medicaid causes budget headache in Wash. state; Minn. plan to cut health services a surprise; Midwife access issues in N.C.

Fibromyalgia: an interview with Dr Frederick Wolfe, University of Kansas School of Medicine

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Dotarem gets FDA approval for use in patients undergoing CNS MRI

Migraine severity may be predicted by blood levels of fat cell hormone

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

New procedure to treat pseudotumor cerebri

Study shows brain areas undergo measureable volume loss after concussion

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Laboratorios Grifols, Cadence announce new supply agreement for OFIRMEV

FDA accepts AMAG’s Feraheme sNDA for review

Mirabegron reduces frequency of incontinence episodes in phase III trial

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Orofacial treatment beneficial for headache plus temporomandibular disorder

AHRF to present free symposium on dizziness and balance disorders

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Headache News and Research

Latest Headache News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in